Therapeutic Uses of Rituximab in Pediatrics

Rituximab Therapy in Pediatrics

Chief Mentor: Dr. A. Narendra (Assistant Professor, Pediatrics)

Pediatric Nephro & Rheum Postgraduate Teaching Suite

MD / DNB Board Review

Biologic Advancements: Targeted B-Cell Depletion

"Residents and interns, Rituximab has transformed the management of refractory pediatric autoimmune and renal conditions. Master its chimeric molecular structure, distinct mechanisms of cell death, and clinical indications for your theory papers and clinical grand rounds."

— Dr. A. Narendra

High-Yield Examination Blueprints

Molecular Identification: Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody (IgG1 kappa) targeted explicitly against the CD20 antigen found on the surface of B-lymphocytes.

B-Cell Lifespan Targeting Specificity:

• Expressed prominently on: Pre-B cells, mature B cells, and memory B cells.
• Crucial Exam Fact: It spares hematopoietic stem cells and mature **plasma cells** (as plasma cells lose the CD20 marker). Hence, baseline immunoglobulin production is partially preserved.

Three Triad Mechanisms of B-Cell Lysis:

1. Complement-Dependent Cytotoxicity (CDC): Rituximab binding triggers the classical complement pathway, generating the membrane attack complex ($MAC$) to punch holes in the B-cell membrane.
2. Antibody-Dependent Cellular Cytotoxicity (ADCC): Natural Killer ($NK$) cells and macrophages recognize the Fc portion of Rituximab, releasing perforins and granzymes to lyse the B cell.
3. Direct Induction of Apoptosis: Cross-linking of CD20 directly activates intracellular caspase pathways, accelerating programmed cell death.

1. Steroid-Dependent Nephrotic Syndrome (SDNS) & Frequently Relapsing NS (FRNS)

Rituximab serves as a highly effective steroid-sparing agent. It helps maintain long-term remission, breaks the cycle of frequent relapses, and allows for the safe taper of toxic corticosteroids and calcineurin inhibitors.

2. Refractory Steroid-Resistant Nephrotic Syndrome (SRNS)

In children with non-genetic forms of SRNS who fail to achieve remission with Cyclosporine or Tacrolimus, Rituximab can be utilized to reduce proteinuria and protect long-term GFR.

3. Lupus Nephritis (Class III, IV, or V)

Indicated in severe, active pediatric lupus nephritis that shows an inadequate response to standard induction therapy with Mycophenolate Mofetil (MMF) or Cyclophosphamide.

Rheumatology Systemic Disease Indications:

• ANCA-Associated Vasculitis: Granulomatosis with Polyangiitis (GPA / Wegener's) and Microscopic Polyangiitis (MPA). Rituximab is FDA-approved for induction therapy here, matching Cyclophosphamide efficacy with less gonadal toxicity.
• Severe Juvenile Dermatomyositis (JDM): Indicated in refractory JDM presenting with severe skin ulcerations or progressive proximal muscle weakness unresponsive to high-dose pulse steroids and Methotrexate.

Hematology Indications (Antibody-Mediated Destruction):

• Refractory Immune Thrombocytopenia (ITP): Used in chronic or severe ITP with high bleeding risk that fails to respond to IVIg, Anti-D, or corticosteroids.
• Autoimmune Hemolytic Anemia (AIHA): Highly effective in severe warm or cold-antibody AIHA and **Evans Syndrome** (co-existing ITP and AIHA).

Dosing Protocols: Typically administered as **$375 \text{ mg/m}^2$ IV infusion** once weekly for 2 to 4 doses, or alternative rheumatology regimens ($750 \text{ mg/m}^2$ two doses, 2 weeks apart).

Adverse Reactions Checklist

• Acute Infusion Reactions: Fever, chills, bronchospasm, and hypotension (caused by massive cytokine release).
• Severe Cytopenias: Late-onset neutropenia can occur months post-therapy.
• Hypogammaglobulinemia: Prolonged B-cell depletion leads to low IgG levels, increasing the risk of sinopulmonary infections.
• PML Risk: Progressive Multifocal Leukoencephalopathy (rare JC virus reactivation).

Dr. Narendra's Screening Protocol

• Pre-medication Mandate: Always give Paracetamol, Pheniramine/Diphenhydramine, and Hydrocortisone 30 minutes before starting the infusion.
• Viral Screening: Screen for Hepatitis B (HBsAg and Anti-HBc) before the first dose to prevent fatal reactivation.
• Immunization Rule: Complete all required live vaccines at least 4 weeks before starting therapy. Live vaccines are contraindicated during B-cell depletion.

Clinical Mechanism Maps & Algorithms

A Molecular Mechanism of B-Cell Depletion

Visual overview of how Rituximab targets the CD20 receptor on B cells, initiating complement activation (CDC) and natural killer cell recruitment (ADCC).

B Refractory Steroid-Resistant Nephrotic Syndrome Workup

Clinical workup pathway where B-cell depletion therapy is introduced for refractory, non-genetic proteinuric disease.

C Severe Autoimmune Mucocutaneous Disease Target: Pemphigus

Severe oral mucosal blistering in Pemphigus Vulgaris. Rituximab is used to clear autoantibodies directed against desmogleins.

Interactive Board MCQ Hub

Q1. Rituximab is a monoclonal antibody engineered against which specific cell-surface cluster designation (CD) marker?

A) CD19 B) CD20 C) CD3

D) CD25

Q2. Which of the following B-lineage cells is completely spared by Rituximab therapy due to the loss of its specific target surface marker?

A) Pre-B cells B) Mature B cells C) Memory B cells D) Terminally differentiated Plasma cells

Q3. Which viral infection template must be universally screened for via serology in all pediatric patients before initiating the first dose of Rituximab?

A) Hepatitis B Virus (HBV) B) Adenovirus C) Parvovirus B19 D) Rotavirus

Q4. What is the standard single dose of Rituximab utilized for managing steroid-dependent or refractory frequently relapsing nephrotic syndrome in children?

A) 10 mg/kg IV B) 150 mg/m² IV C) 375 mg/m² IV D) 750 mg/m² IV

Q5. In children with severe systemic lupus erythematosus (SLE), Rituximab is typically classified under which category of therapeutic indications?

A) First-line routine therapy for uncomplicated cutaneous lupus B) Rescue therapy for severe, refractory Lupus Nephritis failing standard induction C) Prophylactic agent for asymptomatic positive ANA titers D) Replacement for basic hydroxychloroquine maintenance

Q6. What is the mechanism of cell death that occurs when Rituximab cross-links CD20 and directly triggers intracellular caspase enzymatic cascades?

A) Pyretoprosis B) Complement Activation C) Natural Killer cell phagocytosis D) Direct induction of Apoptosis

Q7. The combined presentation of autoimmune hemolytic anemia (AIHA) along with immune thrombocytopenia (ITP) is known as what syndrome?

A) Wiskott-Aldrich Syndrome B) Alport Syndrome C) Evans Syndrome D) Kasabach-Merritt Syndrome

Q8. Which long-term infectious risk condition can occur due to long-term B-cell suppression and a resulting drop in serum IgG levels after multiple cycles of Rituximab?

A) Prolonged Hypogammaglobulinemia B) Severe Hypernatremia C) Primary hyperparathyroidism D) Acute respiratory alkalosis

Q9. Which neurodegenerative disease caused by the reactivation of the latent JC virus carries a rare but serious warning tracking profile during Rituximab therapy?

A) Subacute Sclerosing Panencephalitis (SSPE) B) Progressive Multifocal Leukoencephalopathy (PML) C) Multiple Sclerosis flare D) Guillain-Barré Syndrome

Q10. How long before initiating Rituximab therapy must any mandatory live viral vaccines be completed to ensure proper safety parameters?

A) 24 hours prior B) At least 4 weeks prior C) Concurrent administration is fine D) 6 months post-infusion only

Quiz Performance Tracker

0 / 10

Updates instantly as you click 'Verify Answer' in the MCQs tab.

Pre-Infusion Checklist

• Complete HBV Serology Screening
• Document baseline IgG, IgA, IgM levels
• Verify CBC with absolute neutrophil count
• Confirm no live vaccines were given in past 4 wks

Dr. Narendra's PG Pearls

"When writing your answers on Steroid-Dependent Nephrotic Syndrome, make sure to highlight the **CD20 B-cell depletion remission axis**. Rituximab doesn't just clear standard autoantibodies; it also helps stabilize the podocyte actin cytoskeleton directly by preventing the downregulation of sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b) during severe systemic exposures."